{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-24-000103","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.958866+00:00","generated_at":"2026-06-03T03:32:17.025772+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pfizer Q1 revenue $14.9B (-20% YoY); adj. EPS $0.82; raises FY adj. EPS guidance","bullets":["Q1 revenue $14.9B, operational decline 19% YoY; ex-COVID products grew 11% operationally.","Reported diluted EPS $0.55; adjusted diluted EPS $0.82 (includes $0.11 favorable Paxlovid return adjustment).","Full-year 2024 revenue guidance reaffirmed at $58.5-$61.5B; adjusted EPS guidance raised to $2.15-$2.35.","Cost realignment program on track to deliver at least $4 billion net cost savings by end of 2024.","Notable approvals: Beqvez (hemophilia B) FDA approval, Prevenar 20 (pediatrics) EU approval, Tivdak full FDA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-24-000103","json":"https://secwatch.observer/filing/0000078003-24-000103.json","markdown":"https://secwatch.observer/filing/0000078003-24-000103.md","text":"https://secwatch.observer/filing/0000078003-24-000103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000103/0000078003-24-000103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000103/pfe-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:32:17.025772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49b9335ca2f4b1e455976c85fe3c529bb980f3ca","claim":"PFIZER INC reported first quarter of 2024 results: revenue $14,879 million, net income $3,115 million, EPS $0.55. Guidance raised.","evidence_excerpt":"First-Quarter 2024 Results ▪ Solid First-Quarter Results Reflect Continued Growth of Key Products and Progress in Executing 2024 Priorities ▪ First-Quarter 2024 Revenues of $14.9 Billion – Expected Decline in Comirnaty (1) and Paxlovid Revenues Drove a Year-Over-Year Operational Decrease in Revenues of 19% – Excluding Contributions from Comirnaty (1) and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000007800324000103/0000078003-24-000103-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Revenue","value":"$14,879 million"},{"label":"Net income","value":"$3,115 million"},{"label":"EPS","value":"$0.55"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}